Literature DB >> 18064422

Presynaptic modulation by endocannabinoids.

David M Lovinger1.   

Abstract

Modulation of neurotransmitter release by G-protein-coupled receptors (GPCRs) is a prominent presynaptic mechanism for regulation of synaptic transmission. Activation of GPCRs located at the presynaptic terminal can decrease the probability of neurotransmitter release. This presynaptic depression involves activation of Gi/o-type G-proteins that mediate different inhibitory mechanisms, including inhibition of voltage-gated calcium channels, activation of potassium channels, and direct inhibition of the vesicle fusion process. A variety of neurotransmitters and modulatory agents can activate GPCRs that produce presynaptic depression. Among these are lipid metabolites that serve as agonists for GPCRs. The discovery of endocannabinoids and their cognate receptors, including the CB1 receptor, has stimulated intense investigation into the neurophysiological roles of these lipid metabolites. It is now clear that presynaptic depression is the major physiological role for the CB1 receptor. Endocannabinoids activate this receptor mainly via a retrograde signaling process in which these compounds are synthesized in and released from postsynaptic neuronal elements, and travel back to the presynaptic terminal to act on the CB1 receptor. This retrograde endocannabinoid modulation has been implicated in short-term synaptic depression, including suppression of excitatory or inhibitory transmission induced by postsynaptic depolarization and transient synaptic depression induced by activation of postsynaptic GPCRs during agonist treatment or synaptic activation. Endocannabinoids and the CB1 receptor also play a key role in one form of long-term synaptic depression (LTD) that involves a longlasting decrease in neurotransmitter release.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18064422     DOI: 10.1007/978-3-540-74805-2_14

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  103 in total

1.  Physiological basis for inhibition of morphine and improgan antinociception by CC12, a P450 epoxygenase inhibitor.

Authors:  Mary M Heinricher; Jennifer J Maire; Delaina Lee; Julia W Nalwalk; Lindsay B Hough
Journal:  J Neurophysiol       Date:  2010-10-06       Impact factor: 2.714

Review 2.  Endocannabinoids in striatal plasticity.

Authors:  David M Lovinger; Brian N Mathur
Journal:  Parkinsonism Relat Disord       Date:  2012-01       Impact factor: 4.891

3.  Purine receptor-mediated endocannabinoid production and retrograde synaptic signalling in the cerebellar cortex.

Authors:  Flora E Kovacs; Peter Illes; Bela Szabo
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

4.  Dopaminergic modulation of endocannabinoid-mediated plasticity at GABAergic synapses in the prefrontal cortex.

Authors:  Chiayu Q Chiu; Nagore Puente; Pedro Grandes; Pablo E Castillo
Journal:  J Neurosci       Date:  2010-05-26       Impact factor: 6.167

Review 5.  Endocannabinoid signalling in reward and addiction.

Authors:  Loren H Parsons; Yasmin L Hurd
Journal:  Nat Rev Neurosci       Date:  2015-09-16       Impact factor: 34.870

6.  Targeting multiple key signaling pathways in melanoma using leelamine.

Authors:  Raghavendra Gowda; SubbaRao V Madhunapantula; Omer F Kuzu; Arati Sharma; Gavin P Robertson
Journal:  Mol Cancer Ther       Date:  2014-03-31       Impact factor: 6.261

7.  Leelamine mediates cancer cell death through inhibition of intracellular cholesterol transport.

Authors:  Omer F Kuzu; Raghavendra Gowda; Arati Sharma; Gavin P Robertson
Journal:  Mol Cancer Ther       Date:  2014-03-31       Impact factor: 6.261

Review 8.  Neural substrates underlying the negative impact of cannabinoid exposure during adolescence.

Authors:  Hanna M Molla; Kuei Y Tseng
Journal:  Pharmacol Biochem Behav       Date:  2020-06-09       Impact factor: 3.533

9.  Mechanism for differential recruitment of orbitostriatal transmission during actions and outcomes following chronic alcohol exposure.

Authors:  Rafael Renteria; Christian Cazares; Emily T Baltz; Drew C Schreiner; Ege A Yalcinbas; Thomas Steinkellner; Thomas S Hnasko; Christina M Gremel
Journal:  Elife       Date:  2021-03-17       Impact factor: 8.140

Review 10.  Using metabotropic glutamate receptors to modulate cocaine's synaptic and behavioral effects: mGluR1 finds a niche.

Authors:  Jessica A Loweth; Kuei Y Tseng; Marina E Wolf
Journal:  Curr Opin Neurobiol       Date:  2013-02-04       Impact factor: 6.627

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.